ArriVent BioPharma, Inc. Common Stock

AVBPNASDAQHealthcare● Active

$31.11

+$0.76(+2.50%)

Market Cap$1.4B

P/E Ratio—

52W High$32.98

52W Low$16.1

Avg Volume532K

Open$32.80

Beta1.42

Insider Trades Ownership Employees

ArriVent BioPharma, Inc. Common Stock (AVBP) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · AVBP · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

ArriVent BioPharma, Inc. Common Stock insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

AVBP insider buying and selling by quarter

AVBP insider selling · AVBP insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

63.9M32.0M0

2024 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · AVBP ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

AVBP executive sell shares · AVBP board member insider trading · AVBP insider trading SEC filing

Showing 15 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Dec 10, 2025	HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10 percent owner	Sale	555,555	$23.37	$12.98M⚡	3,929,117	Form 4
Jul 11, 2025	LaChapelle Robin COO	Option	6,503	$2.28	$15K	135,736	Form 4
Jul 11, 2025	LaChapelle Robin COO	Option	2,600	$2.28	$6K	129,233	Form 4
Jul 11, 2025	LaChapelle Robin COO	Option	2,050	$2.28	$5K	126,633	Form 4
Jan 30, 2024	HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10 percent owner	Purchase	555,555	$18.00	$10.00M⚡	4,484,672	Form 4
Jan 30, 2024	HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10 percent owner	Other	313,076	—	—	3,929,117	Form 4
Jan 30, 2024	HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10 percent owner	Other	3,616,041	—	—	3,616,041	Form 4
Jan 30, 2024	ORBIMED ADVISORS LLC Director	Purchase	222,222	$18.00	$4.00M⚡	1,513,664	Form 4
Jan 30, 2024	ORBIMED ADVISORS LLC Director	Other	469,615	—	—	1,291,442	Form 4
Jan 30, 2024	ORBIMED ADVISORS LLC Director	Other	821,827	—	—	821,827	Form 4
Jan 30, 2024	GORDON CARL L Director	Purchase	222,222	$18.00	$4.00M⚡	1,513,664	Form 4
Jan 30, 2024	GORDON CARL L Director	Other	469,615	—	—	1,291,442	Form 4
Jan 30, 2024	GORDON CARL L Director	Other	821,827	—	—	821,827	Form 4
Jan 30, 2024	HEALY JAMES Director	Purchase	444,444	$18.00	$8.00M⚡	1,696,752	Form 4
Jan 30, 2024	HEALY JAMES Director	Other	1,252,308	—	—	1,252,308	Form 4

HILLHOUSE INVESTMENT MANAGEMENT, LTD.

10 percent owner

Sale

Date

Dec 10

555,555

Price

$23.37

Value

$12.98M ⚡

View Form 4 on SEC.gov

LaChapelle Robin

COO

Option

Date

Jul 11

6,503

Price

$2.28

Value

$15K

View Form 4 on SEC.gov

LaChapelle Robin

COO

Option

Date

Jul 11

2,600

Price

$2.28

Value

$6K

View Form 4 on SEC.gov

LaChapelle Robin

COO

Option

Date

Jul 11

2,050

Price

$2.28

Value

$5K

View Form 4 on SEC.gov

HILLHOUSE INVESTMENT MANAGEMENT, LTD.

10 percent owner

Purchase

Date

Jan 30

555,555

Price

$18.00

Value

$10.00M ⚡

View Form 4 on SEC.gov

HILLHOUSE INVESTMENT MANAGEMENT, LTD.

10 percent owner

Other

Date

Jan 30

313,076

Price

—

Value

—

View Form 4 on SEC.gov

HILLHOUSE INVESTMENT MANAGEMENT, LTD.

10 percent owner

Other

Date

Jan 30

3,616,041

Price

—

Value

—

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Purchase

Date

Jan 30

222,222

Price

$18.00

Value

$4.00M ⚡

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Other

Date

Jan 30

469,615

Price

—

Value

—

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Other

Date

Jan 30

821,827

Price

—

Value

—

View Form 4 on SEC.gov

GORDON CARL L

Director

Purchase

Date

Jan 30

222,222

Price

$18.00

Value

$4.00M ⚡

View Form 4 on SEC.gov

GORDON CARL L

Director

Other

Date

Jan 30

469,615

Price

—

Value

—

View Form 4 on SEC.gov

GORDON CARL L

Director

Other

Date

Jan 30

821,827

Price

—

Value

—

View Form 4 on SEC.gov

HEALY JAMES

Director

Purchase

Date

Jan 30

444,444

Price

$18.00

Value

$8.00M ⚡

View Form 4 on SEC.gov

HEALY JAMES

Director

Other

Date

Jan 30

1,252,308

Price

—

Value

—

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About AVBP insider trading

AVBP insider trades

ArriVent BioPharma, Inc. Common Stock (AVBP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including LaChapelle Robin (COO), HILLHOUSE INVESTMENT MANAGEMENT, LTD. (10 percent owner). Over the past 12 months, 2 insiders have filed transactions with the SEC. AVBP insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For ArriVent BioPharma, Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

AVBP insider trading · 5 questions

The insiders of ArriVent BioPharma, Inc. Common Stock (AVBP) include executives and directors such as LaChapelle Robin (COO), HILLHOUSE INVESTMENT MANAGEMENT, LTD. (10 percent owner), among others. Over the past 12 months, 2 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

AVBP board member insider tradingwho are AVBP insidersAVBP insider rosterArriVent BioPharma, Inc. Common Stock executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026